Literature DB >> 15298075

Gaboxadol. Lundbeck/Merck.

Richard Huckle1.   

Abstract

H Lundbeck A/S, in collaboration with Merck & Co Inc, is developing gaboxadol, a GABAA agonist, for the potential treatment of sleep disorders. The compound is currently undergoing phase III clinical trials.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15298075

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  2 in total

1.  The influence of agonists of GABA(A) and GABA(B) receptors on the formation of the defensive and inhibitory conditioned reflexes.

Authors:  G I Shul'gina; E A Zyablitseva; N S Kositsyn
Journal:  Dokl Biol Sci       Date:  2009 Nov-Dec

2.  The role of GABA(A) receptors in the control of transient lower oesophageal sphincter relaxations in the dog.

Authors:  H Beaumont; A-C Jönsson-Rylander; K Carlsson; S Pierrou; M Ahlefelt; L Brändén; J Jensen; G E Boeckxstaens; A Lehmann
Journal:  Br J Pharmacol       Date:  2008-01-21       Impact factor: 8.739
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.